Telomere homolog
oligonucleotides (T-oligos) activate an innate telomere-based program that leads to multiple anticancer effects. T-oligos act at telomeres to initiate signaling through the Werner
protein and ATM
kinase. We wanted to determine if T-oligos have antiangiogenic effects. We found that T-oligo-treated human
melanoma (MM-AN) cells had decreased expression of
vascular endothelial growth factor (
VEGF),
VEGF receptor 2, angiopoeitin-1 and -2 and decreased
VEGF secretion. T-oligos activated the
transcription factor E2F1 and inhibited the activity of the angiogenic
transcription factor, HIF-1alpha. T-oligos inhibited EC tubulogenesis and total
tumor microvascular density matrix invasion by MM-AN cells and ECs in vitro. In
melanoma SCID xenografts, two systemic T-oligo
injections decreased by 60% (P < .004) total
tumor microvascular density and the functional vessels density by 80% (P < .002). These findings suggest that restriction of
tumor angiogenesis is among the host's innate telomere-based anticancer responses and provide further evidence that T-oligos may offer a powerful new approach for
melanoma treatment.